Toxicity of ligand and antibody-directed ricin A-chain conjugates recognizing the epidermal growth factor receptor
- PMID: 3496342
- DOI: 10.1002/jcp.1041310314
Toxicity of ligand and antibody-directed ricin A-chain conjugates recognizing the epidermal growth factor receptor
Abstract
Approximately equal amounts of 125I-mAb 225 (a monoclonal antibody recognizing the human epidermal growth factor receptor) and 125I-labeled epidermal growth factor (125I-EGF) were bound by HeLa cells. However, these two EGF receptor binding moieties had different fates after binding. Sixty percent of cell-associated 125I-EGF was internalized. The majority of internalized 125I was released from the cell within 2 hr. In contrast, whereas only 30% of bound 125I-mAb 225 was internalized by HeLa cells, the internalized radioactivity remained cell-associated. EGF and mAb 225 were used to construct ricin A-chain (RTA) conjugates. The two chimeric molecules, EGF-RTA and mAb 225-RTA, were equally toxic to human HeLa cells. EGF-RTA was also toxic to murine 3T3 cells. In contrast, mAb 225-RTA was not toxic to 3T3 cells, consistent with the human EGF-receptor specificity of mAb 225. Neither conjugate was cytotoxic to EGF receptor-deficient 3T3-NR6 cells. Rapidity and potency of protein synthesis inhibition of HeLa cells were equivalent for the two chimeric conjugates, as was the degree to which colony-forming ability was reduced. However, ammonium chloride enhanced the toxicity of EGF-RTA but not mAb 225-RTA, suggesting that the two toxic chimeric toxins--like the unconjugated receptor-binding moieties--are processed differently by HeLa cells.
Similar articles
-
HeLa cell mutants resistant to epidermal growth factor ricin A-chain conjugate.J Cell Physiol. 1989 Apr;139(1):42-50. doi: 10.1002/jcp.1041390108. J Cell Physiol. 1989. PMID: 2785116
-
Toxic ligand conjugates as tools in the study of receptor-ligand interactions.J Cell Biochem. 1982;20(2):163-76. doi: 10.1002/jcb.240200208. J Cell Biochem. 1982. PMID: 6188758 Review.
-
Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain.Cancer Res. 1989 Jul 1;49(13):3482-8. Cancer Res. 1989. PMID: 2786451
-
Assessment of ligand effects in intracellular trafficking of ricin A chain using anti-ricin hybridomas.Cancer Res. 1991 Mar 15;51(6):1689-93. Cancer Res. 1991. PMID: 1998959
-
Enhancement of immunotoxin action: manipulation of the cellular routing of proteins.Cancer Treat Res. 1988;37:371-89. doi: 10.1007/978-1-4613-1083-9_20. Cancer Treat Res. 1988. PMID: 2908633 Review. No abstract available.
Cited by
-
Characterization of a monoclonal antibody directed against the epidermal growth factor receptor binding site.Cancer Immunol Immunother. 1991;34(1):37-42. doi: 10.1007/BF01741322. Cancer Immunol Immunother. 1991. PMID: 1760809 Free PMC article.
-
Effects of EGF-dextran-tyrosine-131I conjugates on the clonogenic survival of cultured glioma cells.J Neurooncol. 1992 Nov;14(3):213-23. doi: 10.1007/BF00172597. J Neurooncol. 1992. PMID: 1281225
-
Intracellular trafficking considerations in the development of natural ligand-drug molecular conjugates for cancer.Ann Biomed Eng. 2011 Apr;39(4):1235-51. doi: 10.1007/s10439-011-0280-y. Epub 2011 Feb 25. Ann Biomed Eng. 2011. PMID: 21350890 Free PMC article. Review.
-
EGFR(s) in aging and carcinogenesis of the gastrointestinal tract.Curr Protein Pept Sci. 2010 Sep;11(6):436-50. doi: 10.2174/138920310791824110. Curr Protein Pept Sci. 2010. PMID: 20491625 Free PMC article. Review.
-
An enhanced intracellular delivery platform based on a distant diphtheria toxin homolog that evades pre-existing antitoxin antibodies.EMBO Mol Med. 2024 Oct;16(10):2638-2651. doi: 10.1038/s44321-024-00116-z. Epub 2024 Aug 19. EMBO Mol Med. 2024. PMID: 39160301 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials